Amid The Lipitor Scuffle, What’s Next For Crestor?

Expiration of the Lipitor patent puts tremendous pressure on AstraZeneca’s bestselling statin, Crestor, which accounts for 20% of total revenues. AstraZeneca insists the drug’s value proposition will enable it to withstand the onslaught, but analysts expect a gradual chipping away at market share.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from United States

More from North America